Liver Cancer

 

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (UW09018)
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Emboliztion (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study

Investigator: Edward Lin, MD;   Conditions: Liver Cancer;    Status: Closed;   Study ID: NCT00908752